SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
/x/ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended June 30, 2001
OR
| / / | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 0-19125
ISIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporations or organization) | 33-0336973 (I.R.S. Employer Identification No.) | |
2292 Faraday Avenue, Carlsbad, CA 92008 (Address of principal executive offices, including zip code) | ||
(760) 931-9200
(Registrant's telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
| (1) Yes /x/ No / / | (2) Yes /x/ No / / |
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
| Common stock $.001 par value | 42,247,956 shares | |
| (Class) | (Outstanding at June 30, 2001) |
This amendment to the Form 10-Q, for the quarterly period ended June 30, 2001, is being filed solely to amend Part II, Item 6, Exhibit 10.2.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
| Exhibits | | |
|---|---|---|
| 3.1 | Bylaws of Isis Pharmaceuticals, Inc. | |
| 3.2 | Amended and Restated Certificate of Incorporation filed April 9, 2001 | |
| 10.1 | Agreement between the Registrant and Merck & Co., Inc., dated May 22, 2001 (with certain confidential information deleted) | |
| 10.2 | Master Agreement between the Registrant and Hybridon, Inc., dated May 24, 2001, (with certain confidential information deleted) | |
| 10.3 | Agreement between the Registrant and PE Corporation through the Celera Genomics Group, dated July 9, 2001 (with certain confidential information deleted) |
Not applicable.
2
ISIS PHARMACEUTICALS, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ISIS PHARMACEUTICALS, INC. (Registrant) | ||||
Date: August 15, 2001 | By: | /s/ B. LYNNE PARSHALL B. Lynne Parshall Executive Vice President and Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer) | ||
3
